carvedilol has been researched along with Hibernation, Myocardial in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction." | 9.10 | Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. ( Cleland, JG; Coats, AJ; Lahiri, A; Macfarlane, PW; Mule, JD; Murray, GD; Pennell, DJ; Ray, SG; Vered, Z, 2003) |
| "Carvedilol reduces mortality and improves symptoms and ejection fraction in ischemic heart failure, but its mode of action is not well defined and not all patients respond to treatment." | 9.09 | The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. ( Atkinson, P; Burgess, M; Cleland, JG; Davies, G; Pennell, DJ; Ray, SG; Slomka, P; Webster, J, 2000) |
| "We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction." | 5.10 | Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. ( Cleland, JG; Coats, AJ; Lahiri, A; Macfarlane, PW; Mule, JD; Murray, GD; Pennell, DJ; Ray, SG; Vered, Z, 2003) |
| "Carvedilol reduces mortality and improves symptoms and ejection fraction in ischemic heart failure, but its mode of action is not well defined and not all patients respond to treatment." | 5.09 | The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. ( Atkinson, P; Burgess, M; Cleland, JG; Davies, G; Pennell, DJ; Ray, SG; Slomka, P; Webster, J, 2000) |
| "Carvedilol improves left ventricular (LV) function when heart failure is due to LV systolic dysfunction, but the magnitude of the response is heterogeneous among patients with coronary disease, possibly reflecting the presence or volume of hibernating myocardium." | 5.09 | The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. ( Cleland, JG; Coats, A; Cowley, A; Lahiri, A; MacFarlane, P; Murray, G; Pennel, D; Ray, S, 1999) |
| "Carvedilol treatment of hibernating myocardium results in improved functional recovery after revascularization compared with metoprolol tartrate, and this might partially be related to reduced cardiomyocyte degeneration." | 2.71 | Carvedilol improves myocardial contractility compared with metoprolol in patients with chronic hibernating myocardium after revascularization. ( Diep, TP; Grohmann, B; Gupta, R; Kostin, S; Nowak, B; Schaper, J; Schwarz, ER; Uretsky, BF, 2005) |
| "Carvedilol is an alpha-and beta-blocking agent with antioxidant properties." | 1.33 | In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart. ( Hegna, S; Johansen, OE; Mjøs, OD; Munch-Ellingsen, J; Starkopf, J; Ytrehus, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cleland, JG | 3 |
| Pennell, DJ | 2 |
| Ray, SG | 2 |
| Coats, AJ | 1 |
| Macfarlane, PW | 1 |
| Murray, GD | 1 |
| Mule, JD | 1 |
| Vered, Z | 1 |
| Lahiri, A | 2 |
| Köszegi, Z | 1 |
| Balogh, E | 1 |
| Schwarz, ER | 1 |
| Gupta, R | 1 |
| Diep, TP | 1 |
| Nowak, B | 1 |
| Kostin, S | 1 |
| Grohmann, B | 1 |
| Uretsky, BF | 1 |
| Schaper, J | 1 |
| Starkopf, J | 1 |
| Hegna, S | 1 |
| Johansen, OE | 1 |
| Munch-Ellingsen, J | 1 |
| Mjøs, OD | 1 |
| Ytrehus, K | 1 |
| Davies, G | 1 |
| Burgess, M | 1 |
| Webster, J | 1 |
| Slomka, P | 1 |
| Atkinson, P | 1 |
| Pennel, D | 1 |
| Ray, S | 1 |
| Murray, G | 1 |
| MacFarlane, P | 1 |
| Cowley, A | 1 |
| Coats, A | 1 |
4 trials available for carvedilol and Hibernation, Myocardial
| Article | Year |
|---|---|
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Female; Heart Failure; Hum | 2003 |
Carvedilol improves myocardial contractility compared with metoprolol in patients with chronic hibernating myocardium after revascularization.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Apoptosis; Carbazoles; Carvedilol; Chronic Disease; Corona | 2005 |
The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography, Doppler; | 2000 |
The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; E | 1999 |
3 other studies available for carvedilol and Hibernation, Myocardial
| Article | Year |
|---|---|
[Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Myocardial Stunning; Pla | 2003 |
Myocardial dysfunction: hibernation and remodelling.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Circulation; Heart; Heart Failure; Hum | 2003 |
In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart.
Topics: Adrenergic alpha-Antagonists; Animals; Carbazoles; Carvedilol; Diastole; Ischemic Preconditioning, M | 2006 |